OBJECTIVES: To investigate prospectively whether the presence of pre-plus disease predicts progression to severe retinopathy of prematurity (ROP) requiring laser treatment. METHODS: Posterior retinal video recordings were obtained during 710 indirect ophthalmoscopy examinations of 214 premature infants over a period of 5 years. Two masked experts reviewed short video recordings and determined whether there was plus disease, pre-plus disease, or neither. The primary analysis included results of one examination of the right eye at 33 to 34 weeks' postmenstrual age. The primary outcome was a comparison of the proportion of eyes subsequently requiring laser treatment between the group graded as having pre-plus disease vs the group graded as having neither plus disease nor pre-plus disease. RESULTS: Of 10 eyes with pre-plus disease at 33 to 34 weeks' postmenstrual age, 7 (70%) subsequently required laser treatment; of 154 eyes without pre-plus disease or plus disease at 33 to 34 weeks' postmenstrual age, 14 (9%) subsequently required laser treatment (risk ratio, 7.7; 95% confidence interval, 4.1-14.8; P < .001). The mean time between the examination diagnosing pre-plus disease and laser treatment was 1.6 weeks (range, 1.0-2.4 weeks). When adjusting for birth weight, gestational age, ROP location (zone), and ROP severity (stage), the presence of pre-plus disease at 33 to 34 weeks' postmenstrual age independently predicted the need for laser treatment (adjusted odds ratio, 7.6; 95% confidence interval, 1.4-42.3; P = .02). CONCLUSIONS: Pre-plus disease observed early during the course of ROP is strongly associated with the development of severe ROP requiring laser treatment. The diagnosis of pre-plus disease has prognostic value beyond that already provided by birth weight, gestational age, ROP zone, and ROP stage. Eyes with pre-plus disease should be closely observed to allow optimal timing of intervention.
OBJECTIVES: To investigate prospectively whether the presence of pre-plus disease predicts progression to severe retinopathy of prematurity (ROP) requiring laser treatment. METHODS: Posterior retinal video recordings were obtained during 710 indirect ophthalmoscopy examinations of 214 premature infants over a period of 5 years. Two masked experts reviewed short video recordings and determined whether there was plus disease, pre-plus disease, or neither. The primary analysis included results of one examination of the right eye at 33 to 34 weeks' postmenstrual age. The primary outcome was a comparison of the proportion of eyes subsequently requiring laser treatment between the group graded as having pre-plus disease vs the group graded as having neither plus disease nor pre-plus disease. RESULTS: Of 10 eyes with pre-plus disease at 33 to 34 weeks' postmenstrual age, 7 (70%) subsequently required laser treatment; of 154 eyes without pre-plus disease or plus disease at 33 to 34 weeks' postmenstrual age, 14 (9%) subsequently required laser treatment (risk ratio, 7.7; 95% confidence interval, 4.1-14.8; P < .001). The mean time between the examination diagnosing pre-plus disease and laser treatment was 1.6 weeks (range, 1.0-2.4 weeks). When adjusting for birth weight, gestational age, ROP location (zone), and ROP severity (stage), the presence of pre-plus disease at 33 to 34 weeks' postmenstrual age independently predicted the need for laser treatment (adjusted odds ratio, 7.6; 95% confidence interval, 1.4-42.3; P = .02). CONCLUSIONS: Pre-plus disease observed early during the course of ROP is strongly associated with the development of severe ROP requiring laser treatment. The diagnosis of pre-plus disease has prognostic value beyond that already provided by birth weight, gestational age, ROP zone, and ROP stage. Eyes with pre-plus disease should be closely observed to allow optimal timing of intervention.
Authors: Antonio Capone; Anna L Ells; Alistair R Fielder; John T Flynn; Glen A Gole; William V Good; Jonathan M Holmes; Gerd Holmstrom; Ximena Katz; J Arch McNamara; Earl A Palmer; Graham E Quinn; Michael Shapiro; Michael G J Trese; David K Wallace Journal: Arch Ophthalmol Date: 2006-11
Authors: Clare M Wilson; Kenneth D Cocker; Merrick J Moseley; Carl Paterson; Simon T Clay; William E Schulenburg; Monte D Mills; Anna L Ells; Kim H Parker; Graham E Quinn; Alistair R Fielder; Jeffrey Ng Journal: Invest Ophthalmol Vis Sci Date: 2008-04-11 Impact factor: 4.799
Authors: Chace Moleta; J Peter Campbell; Jayashree Kalpathy-Cramer; R V Paul Chan; Susan Ostmo; Karyn Jonas; Michael F Chiang Journal: Am J Ophthalmol Date: 2017-01-11 Impact factor: 5.258
Authors: Jane S Myung; Rony Gelman; Grant D Aaker; Nathan M Radcliffe; R V Paul Chan; Michael F Chiang Journal: Am J Ophthalmol Date: 2011-10-22 Impact factor: 5.258
Authors: Nikolas N Raufi; Caleb K Morris; Sharon F Freedman; David K Wallace; S Grace Prakalapakorn Journal: J Pediatr Ophthalmol Strabismus Date: 2016-05-01 Impact factor: 1.402
Authors: Jayashree Kalpathy-Cramer; J Peter Campbell; Deniz Erdogmus; Peng Tian; Dharanish Kedarisetti; Chace Moleta; James D Reynolds; Kelly Hutcheson; Michael J Shapiro; Michael X Repka; Philip Ferrone; Kimberly Drenser; Jason Horowitz; Kemal Sonmez; Ryan Swan; Susan Ostmo; Karyn E Jonas; R V Paul Chan; Michael F Chiang Journal: Ophthalmology Date: 2016-08-24 Impact factor: 12.079
Authors: Ramiro S Maldonado; Eric Yuan; Du Tran-Viet; Adam L Rothman; Amy Y Tong; David K Wallace; Sharon F Freedman; Cynthia A Toth Journal: Ophthalmology Date: 2014-01-21 Impact factor: 12.079